Town AR - Search Results

1

Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells.

Yee KW, Schittenhelm M, O'Farrell AM, Town AR, McGreevey L, Bainbridge T, Cherrington JM, Heinrich MC. Yee KW, et al. Among authors: town ar. Blood. 2004 Dec 15;104(13):4202-9. doi: 10.1182/blood-2003-10-3381. Epub 2004 Aug 10. Blood. 2004. PMID: 15304385 Free article.

2

KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size.

Corless CL, McGreevey L, Haley A, Town A, Heinrich MC. Corless CL, et al. Am J Pathol. 2002 May;160(5):1567-72. doi: 10.1016/S0002-9440(10)61103-0. Am J Pathol. 2002. PMID: 12000708 Free PMC article.

3

PDGFRA activating mutations in gastrointestinal stromal tumors.

Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N, Singer S, Griffith DJ, Haley A, Town A, Demetri GD, Fletcher CD, Fletcher JA. Heinrich MC, et al. Science. 2003 Jan 31;299(5607):708-10. doi: 10.1126/science.1079666. Epub 2003 Jan 9. Science. 2003. PMID: 12522257

4

SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo.

O'Farrell AM, Abrams TJ, Yuen HA, Ngai TJ, Louie SG, Yee KW, Wong LM, Hong W, Lee LB, Town A, Smolich BD, Manning WC, Murray LJ, Heinrich MC, Cherrington JM. O'Farrell AM, et al. Blood. 2003 May 1;101(9):3597-605. doi: 10.1182/blood-2002-07-2307. Epub 2003 Jan 16. Blood. 2003. PMID: 12531805 Free article.

5

Absence of BRAF and NRAS mutations in uveal melanoma.

Cruz F 3rd, Rubin BP, Wilson D, Town A, Schroeder A, Haley A, Bainbridge T, Heinrich MC, Corless CL. Cruz F 3rd, et al. Cancer Res. 2003 Sep 15;63(18):5761-6. Cancer Res. 2003. PMID: 14522897

6

KIT mutations are common in testicular seminomas.

Kemmer K, Corless CL, Fletcher JA, McGreevey L, Haley A, Griffith D, Cummings OW, Wait C, Town A, Heinrich MC. Kemmer K, et al. Am J Pathol. 2004 Jan;164(1):305-13. doi: 10.1016/S0002-9440(10)63120-3. Am J Pathol. 2004. PMID: 14695343 Free PMC article.

7

KIT gene deletions at the intron 10-exon 11 boundary in GI stromal tumors.

Corless CL, McGreevey L, Town A, Schroeder A, Bainbridge T, Harrell P, Fletcher JA, Heinrich MC. Corless CL, et al. J Mol Diagn. 2004 Nov;6(4):366-70. doi: 10.1016/S1525-1578(10)60533-8. J Mol Diagn. 2004. PMID: 15507676 Free PMC article.

8

PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib.

Corless CL, Schroeder A, Griffith D, Town A, McGreevey L, Harrell P, Shiraga S, Bainbridge T, Morich J, Heinrich MC. Corless CL, et al. J Clin Oncol. 2005 Aug 10;23(23):5357-64. doi: 10.1200/JCO.2005.14.068. Epub 2005 May 31. J Clin Oncol. 2005. PMID: 15928335 Review.

9

FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248).

Schittenhelm MM, Yee KW, Tyner JW, McGreevey L, Haley AD, Town A, Griffith DJ, Bainbridge T, Braziel RM, O'Farrell AM, Cherrington JM, Heinrich MC. Schittenhelm MM, et al. Leukemia. 2006 Nov;20(11):2008-14. doi: 10.1038/sj.leu.2404374. Epub 2006 Sep 14. Leukemia. 2006. PMID: 16990784

10

Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases.

Heinrich MC, Joensuu H, Demetri GD, Corless CL, Apperley J, Fletcher JA, Soulieres D, Dirnhofer S, Harlow A, Town A, McKinley A, Supple SG, Seymour J, Di Scala L, van Oosterom A, Herrmann R, Nikolova Z, McArthur AG; Imatinib Target Exploration Consortium Study B2225. Heinrich MC, et al. Clin Cancer Res. 2008 May 1;14(9):2717-25. doi: 10.1158/1078-0432.CCR-07-4575. Clin Cancer Res. 2008. PMID: 18451237 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

22 results

Search Page